MIMRYLO
Sep 04, 2026
MIMRYLO Enters the Polycythemia Vera Arena: Can the First-in-Class Hepcidin Mimetic Challenge JAKAFI and BESREMi?
Summary On August 28, 2026, the FDA approved MIMRYLO (rusfertide), developed by Protagonist Therapeutics and commercialized by Takeda, for treating erythrocytosis in adults with polycythemia vera. MIMRYLO is the first approved hepcidin mimetic peptide for PV. It targets the iron-regulation pathway rather tha...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
